Neuron-specific enolase in patients with neurocysticercosis

Journal of the Neurological Sciences

Volumn 217, Issue 1, 2004, Pages 31-35

  Lima, José Eduardo ^a   Takayanagui, Osvaldo Massaiti ^a   Garcia, Luis Vicente ^a   Leite, João Pereira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Albumin quotient; Cerebrospinal fluid; Neurocysticercosis; Neuron specific enolase; Neuronal damage; NSE

Indexed keywords

ALBUMIN; NEURON SPECIFIC ENOLASE;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYST; DEGENERATIVE DISEASE; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INTRACRANIAL HYPERTENSION; MALE; NEUROCYSTICERCOSIS; PATIENT; PERMEABILITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW;

EID: 0346849962     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2003.08.008     Document Type: Article

References (37)

1. Garcia H.H., Evans C.A., Nash T.E., Takayanagui O.M., White A.C. Jr., Botero D.et al. Current consensus guidelines for treatment of neurocysticercosis. Clin. Microbiol. Rev. 15(4):2002;747-756.
2. Roman G., Sotelo J., Del Brutto O., Flisser A., Dumas M., Wadia N.et al. A proposal to declare neurocysticercosis an international reportable disease. Bull. World Health Organ. 78(3):2000;399-406.
3. Restrepo B.I., Aguilar M.I., Melby P.C., Teale J.M. Analysis of the peripheral immune response in patients with neurocysticercosis: evidence for T cell reactivity to parasite glycoprotein and vesicular fluid antigens. Am. J. Trop. Med. Hyg. 65(4):2001;366-370.
4. Grewal J.S., Kaur S., Bhatti G., Sawhney I.M., Ganguly N.K., Mahajan R.C.et al. Cellular immune responses in human neurocysticercosis. Parasitol. Res. 86(6):2000;500-503.
5. White A.C. Jr. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Annu. Rev. Med. 51:2000;187-206.
6. White A.C. Jr. Neurocysticercosis: a major cause of neurological disease worldwide. Clin. Infect. Dis. 24(2):1997;101-113. [quiz 114-5].
7. Fletcher L., Rider C.C., Taylor C.B. Enolase isoenzymes: III. Chromatographic and immunological characteristics of rat brain enolase. Biochim. Biophys. Acta. 452(1):1976;245-252.
8. Marangos P.J., Schmechel D.E. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu. Rev. Neurosci. 10:1987;269-295.
9. Hay E., Royds J.A., Davies-Jones G.A., Lewtas N.A., Timperley W.R., Taylor C.B. Cerebrospinal fluid enolase in stroke. J. Neurol. Neurosurg. Psychiatry. 47(7):1984;724-729.
10. Schaarschmidt H., Prange H.W., Reiber H. Neuron-specific enolase concentrations in blood as a prognostic parameter in cerebrovascular diseases. Stroke. 25(3):1994;558-565.
11. Wunderlich M.T., Ebert A.D., Kratz T., Goertler M., Jost S., Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke. 30(6):1999;1190-1195.
12. Fogel W., Krieger D., Veith M., Adams H.P., Hund E., Storch-Hagenlocher B.et al. Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. Crit. Care Med. 25(7):1997;1133-1138.
13. Schoerkhuber W., Kittler H., Sterz F., Behringer W., Holzer M., Frossard M.et al. Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. Stroke. 30(8):1999;1598-1603.
14. DeGiorgio C.M., Heck C.N., Rabinowicz A.L., Gott P.S., Smith T., Correale J. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology. 52(4):1999;746-749.
15. Zerr I., Bodemer M., Racker S., Grosche S., Poser S., Kretzschmar H.A.et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet. 345(8965):1995;1609-1610.
16. Kropp S., Zerr I., Schulz-Schaeffer W.J., Riedemann C., Bodemer M., Laske C.et al. Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 261(1-2):1999;124-126.
17. Green A.J., Thompson E.J., Stewart G.E., Zeidler M., McKenzie J.M., MacLeod M.A.et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry. 70(6):2001;744-748.
18. Aksamit A.J. Jr., Preissner C.M., Homburger H.A. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology. 57(4):2001;728-730.
19. Studahl M., Rosengren L., Gunther G., Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J. Neurol. 247(8):2000;636-642.
20. Del Brutto O.H., Rajshekhar V., White A.C. Jr., Tsang V.C., Nash T.E., Takayanagui O.M.et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. 57(2):2001;177-183.
21. Carpio A., Placencia M., Santillan F., Escobar A. A proposal for classification of neurocysticercosis. Can. J. Neurol. Sci. 21(1):1994;43-47.
22. Sterk M., Oenings A., Eymann E., Roos W. Development of a new automated enzyme immunoassay for the determination of neuron-specific enolase. Anticancer Res. 19(4A):1999;2759-2762.
23. Link H., Tibbling G. Principles of albumin and IgG analyses in neurological disorders: II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand. J. Clin. Lab. Invest. 37(5):1977;391-396.
24. Tibbling G., Link H., Ohman S. Principles of albumin and IgG analyses in neurological disorders: I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 37(5):1977;385-390.
25. Webbe G. Human cysticercosis: parasitology, pathology, clinical manifestations and available treatment. Pharmacol. Ther. 64(1):1994;175-200.
26. Agapejev S. Epidemiology of neurocysticercosis in Brazil. Rev. Inst. Med. Trop. Sao Paulo. 38(3):1996;207-216.
27. Vazquez V., Sotelo J. The course of seizures after treatment for cerebral cysticercosis. N. Engl. J. Med. 327(10):1992;696-701.
28. Royds J.A., Timperley W.R., Taylor C.B. Levels of enolase and other enzymes in the cerebrospinal fluid as indices of pathological change. J. Neurol. Neurosurg. Psychiatry. 44(12):1981;1129-1135.
29. Hardemark H.G., Ericsson N., Kotwica Z., Rundstrom G., Mendel-Hartvig I., Olsson Y.et al. S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J. Neurosurg. 71(5 Pt. 1):1989;727-731.
30. Cunningham R.T., Young I.S., Winder J., O'Kane M.J., McKinstry S., Johnston C.F.et al. Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur. J. Clin. Investig. 21(5):1991;497-500.
31. Cunningham R.T., Watt M., Winder J., McKinstry S., Lawson J.T., Johnston C.F.et al. Serum neurone-specific enolase as an indicator of stroke volume. Eur. J. Clin. Investig. 26(4):1996;298-303.
32. Missler U., Wiesmann M., Friedrich C., Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 28(10):1997;1956-1960.
33. Del Brutto O.H. Single parenchymal brain cysticercus in the acute encephalitic phase: definition of a distinct form of neurocysticercosis with a benign prognosis. J. Neurol. Neurosurg. Psychiatry. 58(2):1995;247-249.
34. Sciutto E., Fragoso G., Fleury A., Laclette J.P., Sotelo J., Aluja A.et al. Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions. Microbes Infect. 2(15):2000;1875-1890.
35. Carpio A. Neurocysticercosis: an update. Lancet, Infect. Dis. 2(12):2002;751-762.
36. Monteiro L., Lopes J., Martins da Silva A. Relationship between cysticercosis and epilepsy. Epilepsia. 40(10):1999;1464-1465.
37. Leite J.P., Terra-Bustamante V.C., Fernandes R.M., Santos A.C., Chimelli L., Sakamoto A.C.et al. Calcified neurocysticercotic lesions and postsurgery seizure control in temporal lobe epilepsy. Neurology. 55(10):2000;1485-1491.